期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

帕洛诺司琼治疗化疗呕吐的临床研究进展 被引量：7

Advances in clinical research on efficacy of palonosetron in treatment of chemotherapy-induced nausea and vomiting
下载PDF
导出
摘要 帕洛诺司琼是第一个获准用于预防迟发性化疗所致恶心、呕吐(chemotherapy-induced nausea and vomiting,CINV)的5-羟色胺3(5-HT3)受体拮抗剂。通过比较,发现帕洛诺司琼治疗急性期CINV至少同第一代5-HT3受体拮抗剂同样有效,对延迟性CINV的疗效优于第一代5-HT3受体拮抗剂。本文综述了帕洛诺司琼的临床研究进展,并探讨了多剂量给予帕洛诺司琼的安全性和有效性。 Palonosetron is the first 5-HT3 receptor antagonist approved for prevention of delayed chemotherapy-induced nausea and vomiting（CINV）.Furthermore,palonosetron is at least as effective as first-generation 5-HT3 receptor antagonists in treatment of acute CINV,and is more effective than first-generation 5-HT3 receptor antagonists in treatment of delayed CINV.The progress of clinical study of palonosetron is reviewed in this article,and the safety and efficacy of multi-dose of palonosetron in treatment of CINV are also discussed.
作者 解李丽 徐先艳
机构地区 海南天源康泽医药科技有限公司制剂室 齐鲁制药有限公司药物研究院制剂室
出处 《药学服务与研究》 CAS CSCD 2010年第1期59-62,共4页 Pharmaceutical Care and Research
关键词 帕洛诺司琼 5-HT3受体拮抗剂 呕吐 化疗 综述 palonosetron 5-HT3 receptor antagonist vomiting chemotherapy review
分类号 R975.4 [医药卫生—药品]
  • 相关文献

参考文献12

  • 1Aapro M S. Palonosetron as an anti-emetic and anti nausea agent in oncology[J]. Ther Clin Risk Manag, 2007,3(6):1009-1020.
  • 2Gralla R, Lichinitser M, Van der Vegt S, et al. Palonosetron improves prevention of chemotherapy induced nausea and vomiting following moderately emetogenic chemotherapy: results of a double blind randomized phase Ⅲ trial comparing single doses of palonosetron with ondansetron [J]. Ann Oncol, 2003, 14(10):1570-1577.
  • 3Aapro M S, Grunberg S M, Manikhas G M, etal. A phase Ⅲ, double blind, randomized trial of palonosetron compared with ondansetron in preventing chemotherapy-induced nausea and vomiting following highly ernetogenic chemotherapy[J]. Ann Oncol, 2006, 17(9): 1441-1449.
  • 4李志强,徐建明,刘端祺,张贺龙,王宝成,张沂平,欧阳学农,陈正堂,陶敏,高亚杰,王岩,李晓玲,刘烈军.盐酸帕洛诺司琼预防中重度化疗致吐药引起恶心呕吐的Ⅱ期临床研究[J].临床肿瘤学杂志,2009,14(6):487-490. 被引量：36
  • 5Sepulveda Vidosola A C, Betanzos-Cabrera Y, Lastiri G G, et al. Palonosetron hydroehloride is an effective and safe option to prevent ehemotherapy-indueed nausea and vomiting in children[J]. Arch Med Res, 2008, 39(6):601-606.
  • 6Eisenberg P, Figueroa-Vadillo J, Zamora R, et al. Improved prevention of moderately emetogenic chemotherapy-induced nausea and vomiting with palonosetron, a pharmacologically novel5-HT3 receptor antagonist[J]. Cancer, 2003,98(11): 2473-2482.
  • 7Saito M, Aogi K, Sekine I, et al, Palonosetron plus dexamethasone versus granisetron plus dexamethasone for prevention of nausea and vomiting during chemotherapy: a double-blind, double-dummy, randomised, comparative phase Ⅲ trial[J]. Lancet Oncol, 2009, 10(2) :15 124.
  • 8陈映霞,秦叔逵,程颖,陈振东,李进,张清媛,潘良熹.盐酸帕洛诺司琼预防化疗性恶心呕吐的多中心双盲随机对照临床研究[J].临床肿瘤学杂志,2007,12(3):161-165. 被引量：48
  • 9Petru E, Andel J, Angleitner Boubenizek L, et al. Early Austrian multicenter experience with palonosetron as antie metic treatment for patients undergoing highly or moderately emetogenic chemotherapy[J].Wien Med Wochenschr, 2008, 158(5-6):169-173.
  • 10Grote T, Hajdenberg J, Cartmell A, et al. Combination therapy for chemotherapy-induced nausea and vomiting in patients receiving moderately emetogenic chemotherapy: palonosetron, dexamethasone, and aprepitant[J]. J Support Oncol, 2006,4(8): 403-408.

二级参考文献15

  • 1陈艳,丁莉坤,孟玲燕,丁黎,杨林,文爱东.盐酸帕洛诺司琼注射液人体药动学研究[J].中国新药杂志,2007,16(10):806-809. 被引量：14
  • 2Gralla R, Lichinitser M, Van Der Vegt S, et al. Palonosetron improves prevention of chemotherapy-induced nausea and vomiting following moderately emetogenic chemotherapy: results of a double-blind randomized phase Ⅲ trial comparing single doses of palonosetron with ondansetron [ J ]. Ann Oncol, 2003,14 (10) : 1570 - 1577.
  • 3Aapro MS. Palonosetron as an anti-emetic and anti-nausea agent in oncology[ J]. Ther Clin Risk Manag, 2007,3 (6) : 1009 - 1020.
  • 4Siddiqui MA, Scott LJ. Palonosetron [ J ]. Drugs, 2004,64 (10) :1125 - 1132.
  • 5Stohz R, Cyong JC, Shaha, et al. Pharmacokinetic and safety evaluation of palonosetron, a 5-hydroxytryptamine-3 receptor antagonist,in U. S. and Japanese healthy subjects[J]. J Clin Pharmacol, 2004,44(5 ) :520 -531.
  • 6Eisenberg P, Mackintosh FR, Ritch P, et al. Efficacy, safety and pharmacokinetics of palonosetron in patients receiving highly emetogenic cisplatin-based chemotherapy: a dose-ranging clinical study[J]. Ann Oncol, 2004,15(2) :330-337.
  • 7Hunt TL, Gallagher SC, Cullen MT, et al. Evaluation of safety and pharmacokinetics of consecutive multiple-day dosing of palonosetron in healthy subjects [ J ]. J Clin Pharmacol, 2005,45 (5) :589 -596.
  • 8Aapro MS, Grunberg SM, Manikhas GM, et al. A phase Ⅲ, double-blind, randomized trial of palonosetron compared with ondansetron in preventing chemotherapy-induced nausea and vomiting following highly emetogenic chemotherapy [ J ]. Ann Oncol, 2006,17(9) :1441-1449.
  • 9Hesketh PJ.Comparative review of 5-HT3 receptor antagonists in the treatment of acute chemotherapy-induced nausea and vomiting[J].Cancer Invest,2000,18:163-173.
  • 10Geling O,Eichler HG.Should 5-hydroxytryptamine-3 receptor antagonists be administered beyond 24 hours after chemotherapy to prevent delayed emesis? systematic re-evaluation of clinical evidence and drug cost implications[J].J Clin Oncol,2005,23(6):1289-1294.

共引文献75

同被引文献54

  • 1王雷,孙明,方世满.恩丹西酮联合胃复安、地塞米松预防化疗所致呕吐的临床观察[J].中国基层医药,2004,11(5):621-621. 被引量：3
  • 2章云飞,杨青存,邓巧荣.格拉司琼预防术中及术后患者自控镇痛恶心呕吐的观察[J].中国煤炭工业医学杂志,2004,7(12):1187-1187. 被引量：5
  • 3邹豪,陈盛新.药物利用评价的内涵及方法[J].药学实践杂志,1996,14(5):304-307. 被引量：15
  • 4陈映霞,秦叔逵,程颖,陈振东,李进,张清媛,潘良熹.盐酸帕洛诺司琼预防化疗性恶心呕吐的多中心双盲随机对照临床研究[J].临床肿瘤学杂志,2007,12(3):161-165. 被引量：48
  • 5Aapro MS. Palonosetron as art anti-emetic and anti-nausea agent in oncology[J]. Ther Clin Risk Manag,2007,3(6) : 1009-1020.
  • 6Van Ryckeghem F, Van Belle S. Management of chemotherapy- induced nausea and vomiting [J]. Acta Clin Belg. 2010 Sep-Oct;65(5):305-310.
  • 7Wickham R. Best practice management of CINV in oncology pa- tients: II. Antiemetic guidelines and rationale for use [J]. sup- port oncol,2010 Mar-Apr;8(2 Suppl 1):10-15.
  • 8Likun Z, Xiang J, Yi B,et al. A systematic review and meta-anal- ysis of intravenous palonosetron in the prevention of chemothera- py-induced nausea and vomiting in adults [J]. Oneologist,2011; 16(2) :207-16.
  • 9Schwartzberg L, Morrow G, Balu S,etal. Chemotherapy-induced nausea and vomiting: which antiemetic for which therapy? [J]. Oncology,2007 Jul;21(8) :946-953.
  • 10Balu S, Buchner D, Craver C,et al. Palonosetron versus other 5- HT(3) receptor antagonists for prevention of chemotherapy-ln- duced nausea and vomiting in patients with cancer on chemothera- py in a hospital outpatient setting [J]. Clin Ther2011 Apr; 33 (4) :443-455.

引证文献7

二级引证文献36

药学服务与研究
2010年 第1期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部